BioNTech SE
BNTX News Today: Stay Updated with the Latest BioNTech SE News in Real Time
Find BNTX news now at Meyka AI. Stay informed with the latest BioNTech SE stocks updates, including price news, market analysis, and expert insights.
Top 10 Stocks to Buy or Sell Today as Market Volatility Rises
Global stocks market are showing strong volatility in March 2026 as traders digest conflicting signals from geopolitical tensions, rising energy prices, and economic data. The CBOE Volatility Index (VIX), often called Wall Street’s fear gauge, swung sharply this week, jumping above key levels then retreating as markets tried to regain balance. This turbulence is influencing…
BNTX BioNTech SE March 11, 2026 BMO Maintains Outperform
BNTX analyst rating: BMO maintains Outperform March 11, 2026 and lowers price target to $128
BNTX Stock Today: Founders to Exit; PT Cut to $167 – March 12
BNTX stock today: founders to exit by 2026 and Clear Street cuts price target to $167. What this means for leadership, IP, valuation, mRNA pipeline, and key trading levels for German investors.
Pre-market: BioNTech (22UA.F XETRA) down 17.09% to €72.05: outlook under pressure
Pre-market top loser 22UA.F stock falls to €72.05 on XETRA; analysis of drivers, valuation, and Meyka AI forecasts
Morgan Stanley Maintains Overweight Buy on BioNTech SE (BNTX) March 10, 2026
Morgan Stanley maintained ratings on BioNTech SE. Read implications for BNTX analyst rating and Meyka grade B+
BNTX Stock Today, March 10: Founders Exit; Shares Drop 10% on Shock News
BNTX stock today slumps after founders plan exit by end-2026 to start a new mRNA venture. We cover the mRNA licensing deal, share price reaction, and what to watch next.
Moderna Settles COVID Vaccine Patent Dispute for Up to $2.25 Billion
In a major development for the biotech industry and global health sector, Moderna has agreed to settle a long running COVID Vaccine patent dispute for up to $2.25 billion. The agreement closes a key legal battle linked to its blockbuster mRNA based COVID 19 vaccine, widely known as Spikevax. This settlement is one of the…
BNTX Stock Today: January 23 momentum after six-month high, 2026 catalysts
BNTX stock today: momentum after a six-month high, Goldman Sachs upgrade, FDA accelerated pathway for BNT113, and 2026 oncology catalysts German investors should watch.
BNTX News Today: BioNTech Completes CureVac Acquisition, December 19
Explore BioNTech’s latest acquisition of CureVac, enhancing its mRNA capabilities and growth potential. Investing insights included.